The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Morning Overview on MSN
DNA origami nanoparticles show early promise for future HIV vaccines
DNA origami sounds like science fiction, but for HIV vaccine researchers it is becoming a practical design tool. By folding strands of DNA into tiny three-dimensional scaffolds, scientists can arrange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results